36 results about "Chimpanzee adenovirus" patented technology

The present invention provides recombinant replication-defective adenoviral vectors derived from chimpanzee adenoviruses and methods for generating recombinant adenoviruses in human E1-expressing cell lines. The invention also provides compositions and methods suitable for use for the delivery and expression of transgenes encoding immunogens against which a boosted immune response is desired. The invention further provides methods of generating clinical grade vector stocks suitable for use in humans. In a particular embodiment the invention contemplates the use of vectors comprising transgenes which encode tumor associated antigens in vaccines and pharmaceutical compositions for the prevention and treatment of cancer.

The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

The invention relates to an expression vector based on an adenovirus AdC68 and a construction method thereof. By improving a construction method, the vaccine vector based on a chimpanzee adenovirus AdC68 genome is constructed. The vaccine vector can be applied to preparation of a vaccine capable of high-efficiency expression and having good immunogenicity.

The invention relates to an expression vector based on adenovirus AdC7 and its construction method. An effective strategy is designed for successfully construct the new expression vector based on chimpanzee adenovirus AdC7. The vaccine vector can be applied to the preparation of high expression viral vaccines with good immunogenicity.

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).

The invention relates to a chimpanzee adenovirus vector based Ebola virus vaccine. The chimpanzee adenovirus vector based Ebola virus vaccine is characterized in that replication-defective chimpanzeeadenovirus vector is utilized to build a novel Ebola virus vaccine. The vaccine vector is applicable to preparation of a virus vaccine with efficient expression and high immunogenicity. The Ebola virus vaccine is simple to prepare, low in cost, high in safe, and free from additives.

The invention discloses a zika virus vaccine based on a chimpanzee adenovirus vector and a preparation method thereof, which belong to the field of a biotechnology and virology. A chimpanzee adenovirus AdC 7 is constructed as a replication defective type recombinant expression vector with favorable immunogenicity and hereditary stability, and the novel zika virus vaccine is prepared based on the vector. After mice are immunized through the vaccine, a neutralizing antibody aiming at a zika virus can be effectively induced, so that the mice are protected against being infected, and meanwhile, tissues and organs of the mice can be protected against being damaged.

The invention provides a respiratory syncytial virus full-length pre-fusion glycoprotein nucleotide sequence, a recombinant adenovirus vector and an application product thereof. The full-length pre-fusion glycoprotein nucleotide sequence comprises four mutation loci including S155C, S190F, V207L and S290C, a transmembrane region and an intracellular region of fusion glycoprotein are reserved, anda sequence table of the full-length pre-fusion glycoprotein nucleotide sequence is shown as a sequence 1. The invention further provides a chimpanzee replication-defective recombinant adenovirus vector pChAd63 or a human replication-defective recombinant adenovirus vector pAd26 containing the full-length pre-fusion glycoprotein nucleotide sequence, an initial strain of the adenovirus vector is chimpanzee adenovirus 63 type or human adenovirus 26 type, adenovirus E1 and E3 regions are deleted, and E4orf6 is replaced with human 5-type adenovirus E4orf6. The invention further provides a product applying the recombinant adenovirus. After the recombinant adenovirus vector is used for immunizing animals, the bodies can be induced to generate strong cellular immunity and humoral immunity reactions in a short time, and the generated antibody has high recognition capability on pre-fusion F and has a good immune effect and an immune protection effect.

There is provided adenoviral vectors encoding a mycobacterial antigen derived from a chimp adenovirus, and to related aspects.

Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.

The present invention relates to a new rabies vaccine and method for preparation thereof. The present inventor has constructed, on the basis of a vaccine vector of the genome of chimpanzee adenovirus AdC68, a new type of rabies vaccine vector. The present invention also provides a viral vaccine prepared using said vaccine vector, highly expressed, and having good immunogenicity.

There is provided a method of treating chronic hepatitis B infection (CHB) and / or chronic hepatitis D infection (CHD) in a human, comprising the steps of: a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO); b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and d) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The invention discloses a therapeutic HPV vaccine based on a chimpanzee adenovirus vector as well as a preparation method and application of the therapeutic HPV vaccine. The therapeutic HPV vaccine isan immunogenic HPV recombinant adenovirus vaccine obtained by packaging and processing HPV virus vaccine vector plasmids, and the HPV virus vaccine vector is a replication-defective chimpanzee adenovirus vector. The HPV therapeutic vaccine is constructed by using the replication-defective chimpanzee adenovirus vector, the influence of the pre-stored immunity of a human adenovirus vector in a human body on the vaccine efficacy is overcome, and a vaccine product which is simple to prepare, low in cost, good in safety and free of adjuvants is expected to be obtained. The therapeutic HPV vaccinehas good immunogenicity and anti-tumor efficacy, can induce high-level antigen-specific T cell reaction and anti-tumor efficacy in a mouse body through single muscle immunization, and is expected to show good humoral and cellular immunotherapy effect can be embodied in human clinical tests.

Disclosed herein are chimpanzee adenoviral vectors that include neo-antigen encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

The invention discloses a norovirus vaccine based on a chimpanzee adenovirus vector and a preparation method and application thereof. The norovirus vaccine is prepared by the following steps that a nucleotide sequence of a norovirus target protein is inserted into a recombinant chimpanzee adenovirus vector plasmid to construct a recombinant plasmid, and then packaging and processing are carried out to obtain the norovirus recombinant adenovirus vaccine with immunogenicity. According to the norovirus vaccine, the norovirus vaccine is developed for the first time based on the chimpanzee adenovirus vector, and the vaccine cannot be influenced by a pre-stored adenovirus antibody in a human body; the adenovirus vector vaccine is simple to prepare and good in safety, an adjuvant does not need tobe added, and immunization routes such as muscle immunization or oral immunization can be adopted; and the norovirus preventive vaccine is prepared on the basis of the replication-defective chimpanzee adenovirus vector, and a vaccine product which is easy to prepare, low in cost, good in safety, free of adjuvant and wide in application prospect is expected to be obtained.

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human acomposition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.

There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of:a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); andc) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The invention provides a novel chimpanzee adenovirus vector as well as a construction method and application thereof. The novel chimpanzee adenovirus vector has higher virus titer. The invention also provides a method for measuring a virus titer of the chimpanzee adenovirus vector. The chimpanzee adenovirus annular vector is creatively constructed through a shuttle plasmid, E1 and E3 are knocked out through CRISPR / Cas9, and a replication-defective chimpanzee adenovirus vector is constructed. The chimpanzee adenovirus vector does not have a preexisting antibody in people, knockout of the E1 and the E3 is safe, and meanwhile, the chimpanzee adenovirus vector is remarkably different from E1 of human adenovirus type 5 in 293 cells, so that recovery mutation (RCA) can be greatly avoided, and the chimpanzee adenovirus vector is safer. After passage of dozens of generations, the stability of a constructed novel coronavirus vaccine is very high, mutation is not caused, and very strong humoral immunity and cellular response can be induced in a mouse model.

The invention discloses a chimpanzee adenovirus vaccine for preventing and treating highly-expressed WT1 tumor. A new means for treating breast cancer is provided, a WT1 (Wilm's tumor 1) gene is selected as a target site, a chimpanzee adenovirus is selected as a vector, and a recombinant chimpanzee adenovirus vaccine for expressing WT1 and (GM-CSF)-P2A-(IL-4)-F2A-(WT1) is used for successfully preventing breast cancer and prolonging the lifetime of mice suffering from breast cancer. An experimental foundation is laid for the clinical application of the vaccine, and a prompting effect for the treatment on other tumors is achieved.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

The invention discloses a double antibody sandwich enzyme-linked immunosorbent assay method for detecting chimpanzee adenoviruses AdC68 and belongs to the technical field of immunoassay. The method uses a purified rabbit anti-AdC68 antibody as a coated antibody, purified recombinant ADC68GFP as a standard product, a HRP enzyme-labeled goat anti-adenovirus HEXON antibody as an enzyme-labeled antibody, PBST containing 2% of sheep serum as a sample diluent and a double antibody sandwich method to detect the chimpanzee adenovirus AdC68 antigen, a viral protein, titer and virus particles. The method has high specificity, sensitivity and precision. Compared with the common UV method for measuring virus particles and the plaque method for measuring virus titer, the method has a wide use range andis suitable for on-line detection of the recombinant chimpanzee adenovirus in the purification process. The method can fast estimate the amount of viruses in the preparation of AdC68 and guide the upstream virus culture and downstream purification process.

Disclosed are a chimpanzee adenovirus vector-based zika virus vaccine and a preparation method therefor, belonging to the fields of biotechnology and virology. A chimpanzee adenovirus AdC7 is constructed as a replication defective recombinant expression vector. The vector has good immunogenicity and genetic stability, and a novel zika virus vaccine is prepared on the basis of the vector. Neutralizing antibodies against zika virus are effectively induced in mice which have been immunised with the vaccine, thereby protecting the mice from being infected, and also protecting the tissues and organs of the mice from being damaged.